December 22
QLT Announces Divestment of QLT USA, Inc.'s Generic Dermatology and Manufacturing Business
PDF version
December 19
QLT Signs Research Collaboration and Option Agreement with Wilmer Eye Institute at Johns Hopkins University for Research and Development of Potential Treatments for Dry AMD
December 1
Eligard® Six-Month Formulation Approved in Germany
November 28
Dr. Bruce Carter Joins QLT's Board of Directors
November 7
QLT Announces Positive Findings From Phase IV G6PD Deficiency Study for Aczone™ in Acne
November 6
QLT Announces Jury Decision on Trial of Massachusetts Eye and Ear Infirmary Litigation
October 26
QLT Announces Q3 Results for 2006, Updates Guidance, and Implements Cost Reductions
October 19
QLT Announces Visudyne® Sales for the Third Quarter of 2006 and Updates Annual Sales Guidance
October 6
QLT Provides Update on Massachusetts Eye and Ear Infirmary Litigation
September 14
QLT Announces Final Results of Tender Offer
September 11
QLT Announces Preliminary Results of Tender Offer
August 3
QLT Announces Commencement of Tender Offer
July 27
QLT to Repurchase up to 13 Million Common Shares, This Represents Approximately 15% of Shares Outstanding
QLT Announces Q2 Results for 2006 and Provides Further Guidance
July 17
QLT Announces Visudyne� Sales for Second Quarter of 2006
June 13
Dr. Ian John Massey Joins QLT's Board of Directors
May 25
QLT Strengthens Corporate Development and Legal Functions with the Appointment of Peter J. O'Callaghan as Senior Vice President, Corporate Development and General Counsel
May 18
QLT Delays Initiation of Phase IIa Atrigel/Octreotide Program
May 8
QLT Announces TSX Approval of Second Year of Two-Year Share Repurchase Program
April 27
QLT Announces Q1 Results for 2006 and Provides R&D Guidance
April 24
QLT Announces Visudyne� Sales for First Quarter of 2006
April 5
QLT Announces that Court of Appeals Grants Stay of Injunction Against Eligard Sales
QLT Announces Co-Development and Licensing Agreement with Retinagenix for early stage ocular synthetic retinoid program
March 6
QLT Updates on the U.S. Eligard� Patent Litigation
February 27
QLT intends to appeal U.S. Eligard Injunction
QLT's Board of Directors Appoints Robert Butchofsky as CEO
February 22
QLT Announces 2005 Results and Visudyne® Sales Guidance for 2006
February 14
QLT Announces Preliminary Findings from Phase II Clinical Trial of Lemuteporfin-Injectable in BPH
January 20
QLT Announces Trial Court Decision in Ongoing Eligard� Patent Litigation and its Intention to Appeal
January 19
QLT Announces Visudyne® Sales for Fourth Quarter and Fiscal Year 2005
